| [1] |
Ibrahim MA,Kelleni M,Geddawy A.Nonalcoholic fatty liver disease:current and potential therapies[J].Life Sci,2013,92(2):114-118.
|
| [2] |
Day CP,James OF.Steatohepatitis:a tale of two “hits”[J]? Gastroenterology,1998,114(4):842-845.
|
| [3] |
Sambasiva Rao M,Reddy JK.PPARα in the pathogenesis of fatty liver disease[J].Hepatology,2004,40(4):783-786.
|
| [4] |
Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD:potential therapeutic targets[J].Biochim Biophys Acta,2012,1821(5):809-818.
|
| [5] |
Lefebvre P,Chinetti G,Fruchart JC,et al.Sorting out the roles of PPARα in energy metabolism and vascular homeostasis[J].J Clin Invest,2006,116(3):571-580.
|
| [6] |
Ibrahim SH,Kohli R,Gores GJ.Mechanisms of lipotoxicity in NAFLD and clinical implications[J].J Pediatr Gastroenterol Nutr,2011,53(2):131-140.
|
| [7] |
Cusi K.Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis:pathophysiology and clinical implications[J].Gastroenterology,2012,142(4):711-725.
|
| [8] |
Bastard JP,Maachi M,Lagathu C,et al.Recent advances in the relationship between obesity,inflammation,and insulin resistance[J].Eur Cytokine Netw,2006,17(1):4-12.
|
| [9] |
Begriche K,Igoudjil A,Pessayre D,et al.Mitochondrial dysfunction in NASH:causes,consequences and possible means to prevent it[J].Mitochondrion,2006,6(1):1-28.
|
| [10] |
Gomez-Lechon MJ, Donato MT, Martínez-Romero A, et al. A human hepatocellular in vitro model to investigate steatosis[J].Chem Biol Interact,2007,165(2):106-116.
|
| [11] |
Li Y.Heaptoprotective effect of uygur drug cichorium glandulosum and determination of the majoractive(维药毛菊苣保肝作用及有效成分含量测定)[D].Urumqi:Xinjiang Medical University,2012.
|
| [12] |
Cavin C,Delannoy M,Malnoe A,et al.Inhibition of the expression and activity of cyclooxygenase-2 by chicory extract[J].Biochem Biophys Res Commun,2005,327(3):742-749.
|
| [13] |
Wu YB,Zheng LJ,Wu JG,et al.Antioxidant activities of extract and fractions from receptaculum nelumbinis and related flavonol glycosides[J].Int J Mol Sci,2012,13(6):7163-7173.
|
| [14] |
Ho L,Ferruzzi MG,Janle EM,et al.Identification of brain-targeted bioactive dietary quercetin-3-O-glucuronide as a novel intervention for Alzheimer′s disease[J].FASEB J,2013,27(2):769-781.
|
| [15] |
Derlindati E,Dall′Asta M,Ardigò D,et al.Quercetin-3-O-glucuronide affects the gene expression profile of M1 and M2a human macrophages exhibiting anti-inflammatory effects[J].Food Funct,2012,3(11):1144-1152.
|
| [16] |
Boden G.Obesity,insulin resistance and free fatty acids[J].Curr Opin Endocrinol Diabetes Obes,2011,18(2):139-143.
|
| [17] |
Georgiadi A,Kersten S.Mechanisms of gene regulation by fatty acids[J].Adv Nutr,2012,3(2):127-134.
|
| [18] |
Zhang C,Wang G,Zheng Z,et al.Endoplasmic reticulum-tethered transcription factor cAMP responsive element-binding protein,hepatocyte specific,regulates hepatic lipogenesis,fatty acid oxidation,and lipolysis upon metabolic stress in mice[J].Hepatology,2012,55(4):1070-1082.
|
| [19] |
Serra D,Mera P,Malandrino MI,et al.Mitochondrial fatty acid oxidation in obesity[J].Antioxid Redox Signal,2013,19(3):269-284.
|
| [20] |
Jeppesen J,Kiens B.Regulation and limitations to fatty acid oxidation during exercise[J].J Physiol,2012,590(5):1059-1068.
|
| [21] |
Mannaerts GP,Van Veldhoven PP,Casteels M.Peroxisomal lipid degradation via β- and α-oxidation in mammals[J].Cell Biochem Biophys,2000,32(1/2/3):73-87.
|
| [22] |
Cintolesi A,Rodríguez-Moyá M,Gonzalez R.Fatty acid oxidation:systems analysis and applications[J].Wiley Interdiscip Rev Syst Biol Med,2013,5(5):575-585.
|
| [23] |
Desvergne B,Wahli W.Peroxisome proliferator-activated receptors:nuclear control of metabolism[J].Endocr Rev,1999,20(5):649-688.
|
| [24] |
Issemann I,Green S.Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators[J].Nature,1990,347(6294):645-650.
|
| [25] |
Martins AR,Nachbar RT,Gorjao R,et al.Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids:importance of the mitochondrial function[J].Lipids Health Dis,2012,11(30):1-11.
|
| [26] |
Harano Y,Yasui K,Toyama T,et al.Fenofibrate,a peroxisome proliferator-activated receptor α agonist,reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver[J].Liver Int,2006,26(5):613-620.
|
| [27] |
Schmilovitz-Weiss H,Hochhauser E,Cohen M,et al.Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease-a historical prospective[J].Lipids Health Dis,2013,12(41):1-7.
|
下载:
